Citigroup Cuts Kenvue (NYSE:KVUE) Price Target to $20.00

Key Points

• Citigroup has reduced its price target for Kenvue (NYSE:KVUE) from $22.00 to $20.00, maintaining a "neutral" rating, suggesting potential upside of 9.84% from the previous close.
• Other analysts, including Evercore ISI and Bank of America, have also decreased their price targets for Kenvue, with a consensus price target now at $24.04.
• Kenvue reported a 4.0% decline in year-over-year revenue for its most recent quarter, with earnings per share slightly beating analysts' expectations.

Kenvue (NYSE:KVUE - Get Free Report) had its target price lowered by research analysts at Citigroup from $22.00 to $20.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a "neutral" rating on the stock. Citigroup's price target suggests a potential upside of 9.84% from the company's previous close.

Several other analysts have also commented on the company. Evercore ISI dropped their target price on Kenvue from $25.00 to $23.00 and set an "in-line" rating on the stock in a report on Monday, September 8th. Bank of America lowered their price target on Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a research note on Tuesday, July 15th. Barclays reduced their price objective on Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Tuesday, July 15th. Canaccord Genuity Group reduced their price objective on Kenvue from $29.00 to $26.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Finally, Royal Bank Of Canada reduced their target price on Kenvue from $24.00 to $22.00 and set a "sector perform" rating on the stock in a research report on Friday, August 8th. Five investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Kenvue currently has an average rating of "Hold" and a consensus price target of $24.04.

Kenvue Trading Down 4.1%

Kenvue stock opened at $18.21 on Tuesday. The stock has a 50-day moving average of $21.09 and a two-hundred day moving average of $22.19. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. Kenvue has a one year low of $17.15 and a one year high of $25.17. The stock has a market cap of $34.94 billion, a PE ratio of 24.61, a price-to-earnings-growth ratio of 2.73 and a beta of 0.83.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The company had revenue of $3.84 billion during the quarter, compared to analysts' expectations of $3.94 billion. During the same period last year, the business posted $0.32 earnings per share. The firm's revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, research analysts anticipate that Kenvue will post 1.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Pittenger & Anderson Inc. acquired a new position in shares of Kenvue during the first quarter worth about $30,000. Trust Co. of Vermont lifted its stake in shares of Kenvue by 266.8% during the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company's stock worth $33,000 after purchasing an additional 1,150 shares in the last quarter. TruNorth Capital Management LLC purchased a new stake in shares of Kenvue during the first quarter valued at approximately $36,000. Truvestments Capital LLC purchased a new stake in shares of Kenvue during the first quarter valued at approximately $37,000. Finally, Clal Insurance Enterprises Holdings Ltd raised its stake in shares of Kenvue by 378.5% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock valued at $39,000 after purchasing an additional 1,287 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.